RCS - BSF Enterprise PLC - Participation in The ThinkEquity Conference

BSF EnterpriseAnnouncement

09/10/2023 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231009:nRSI4124Pa&default-theme=true

RNS Number : 4124P  BSF Enterprise PLC  09 October 2023

9 October 2023

BSF Enterprise PLC

("BSF" or the "Company")

 

Participation in The ThinkEquity Conference

 

BSF Enterprise PLC (LSE: BSFA) (OTCQB: BSFAF), a company focused on unlocking
the next generation of biotechnological solutions using cell-based tissue
engineering, will be participating in The ThinkEquity Conference, which will
take place on October 19, 2023, at The Mandarin Oriental Hotel in New York.

 

Che Connon, CEO and Director will be presenting at 10:30 AM ET on October
19th. Interested parties can register to attend here.
(https://api.newsfilecorp.com/redirect/55J7ziVvko) Members of the BSF
Enterprise PLC management will also be holding one-on-one investor meetings
throughout the day.

 

About BSF Enterprise PLC

 

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors. It owns 100% of 3D
Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is
already producing human corneas to help restore vision to millions of people
and successfully produced the UK's first high-quality lab-grown meat from its
laboratory in Newcastle in 2023. BSF aims to deliver growth to shareholders
through the continued commercialisation of 3DBT's IP, which has multiple
applications, as well as through M&A. It aims to acquire a suite of
technologies that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers, wholesalers and
distributors to help manufacture the products at scale.

 

About The ThinkEquity Conference

 

The ThinkEquity Conference will gather industry insiders, investors and
leading executives from around the world on October 19th in New York.
Attendees can expect a full day of company presentations, one-on-one investor
meetings, networking and more.

 

Featured sectors include AI, Technology, Biotechnology, EV/EV Infrastructure,
Metals and mining and Energy. To register to attend The ThinkEquity
Conference, please follow this link.
(https://api.newsfilecorp.com/redirect/LGR5VSYK1O)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                              0207 186 9000

 Isabella Pierre                          0207 186 9927

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas for testing to
help restore vision to millions of people. Building on this success, it has
produced the UK's first high quality lab-grown meat from its laboratory in
Newcastle, transforming the meat-production industry towards an ethical and
sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKOWROUURRRA